WO2024183811 - ANTI-5T4 ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2024/183811
Publication Date
12.09.2024
International Application No.
PCT/CN2024/080719
International Filing Date
08.03.2024
Title **
[English]
ANTI-5T4 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-5T4 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
Inventors
HAN, Yanfei
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
HAN, Zhenyan
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
SHANG, Chengzhang
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
SHEN, Yuelei
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
Priority Data
PCT/CN2023/080242
08.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2882 | |
| EPO | Filing, Examination | 36109 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 20035 |
Total: 60132 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are anti-5T4 (5T4 oncofoetal antigen) antibodies, antigen-binding fragments thereof, antibody-drug conjugate (ADC) derived therefrom, and the uses thereof.[French]
L'invention concerne des anticorps anti-5T4 (antigène oncofœtal 5T4), des fragments de liaison à l'antigène de ceux-ci, un conjugué anticorps-médicament (ADC) dérivé de ceux-ci, et leurs utilisations.